Associated Papers
Genomic ALK alterations in primary and relapsed neuroblastoma.
Rosswog C et al.
British Journal of Cancer, 2023
36807339 (PubMed )
Supplement: 41416_2023_2208_MOESM1_ESM.pdf
Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing.
Szymansky A et al.
Journal of Personalized Medicine, 2021
34442335 (PubMed )
Supplement: jpm-11-00691-s001.zip › S11-SNVs_reference_cohort.xlsx › Tabelle1
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
34630336 (PubMed )
Supplement: Table_1.xlsx › Tab2
Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
Javanmardi N et al.
Scientific Reports, 2019
Patient-Derived Xenograft Models Reveal Intratumor Heterogeneity and Temporal Stability in Neuroblastoma.
Braekeveldt N et al.
Cancer Research, 2018
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.
Ma X et al.
Nature, 2018
29489755 (PubMed )
Supplement: NIHMS939556-supplement-Table_2-7.xlsx › TableS5
Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.
Mossé YP
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
Lambertz I et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Bresler SC et al.
Cancer Cell, 2014
Select a paper to view details